Literature DB >> 7495736

The two novel MHC class II transactivators RFX5 and CIITA both control expression of HLA-DM genes.

I Kern1, V Steimle, C A Siegrist, B Mach.   

Abstract

MHC-encoded HLA-DMA and -DMB molecules are atypical MHC chains that play an essential role in antigen presentation by MHC class II molecules. They resemble both MHC class I and II molecules but are not expressed at the cell surface. From the study of MHC class II regulatory mutants, it was found recently that two novel transactivators, CIITA and RFX5, are essential for the control of MHC class II gene expression. We report here that CIITA and RFX5, although operating at different levels of transcriptional control, are also both essential regulators of HLA-DMA and -DMB genes. This is true for both the constitutive and the inducible mode of DM gene expression. Indeed, both CIITA and RFX5 cDNA can correct the HLA-DMA and -DMB gene expression defect in the respective regulatory mutants. The involvement of these two transcription factors accounts for the coordinate expression of MHC class II and HLA-DM, two sets of molecules that perform quite different functions in the overall process of antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495736     DOI: 10.1093/intimm/7.8.1295

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  24 in total

Review 1.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  Promoter-specific functions of CIITA and the MHC class II enhanceosome in transcriptional activation.

Authors:  Krzysztof Masternak; Walter Reith
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

3.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

4.  Role of Sug1, a 19S proteasome ATPase, in the transcription of MHC I and the atypical MHC II molecules, HLA-DM and HLA-DO.

Authors:  Yaritza Inostroza-Nieves; Prasanna Venkatraman; Zarixia Zavala-Ruiz
Journal:  Immunol Lett       Date:  2012-07-04       Impact factor: 3.685

5.  Interferon-gamma induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells.

Authors:  Giovanna Butticè; Janice Miller; Lin Wang; Barbara D Smith
Journal:  Circ Res       Date:  2006-01-26       Impact factor: 17.367

Review 6.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

7.  The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32.

Authors:  J D Fontes; B Jiang; B M Peterlin
Journal:  Nucleic Acids Res       Date:  1997-06-15       Impact factor: 16.971

8.  Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Authors:  T D Armstrong; V K Clements; B K Martin; J P Ting; S Ostrand-Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

Review 9.  MHC class II regulation by epigenetic agents and microRNAs.

Authors:  Thomas B Tomasi; William J Magner; Jennifer L Wiesen; Julian Z Oshlag; Felicia Cao; Alex N Pontikos; Christopher J Gregorie
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

Review 10.  Fighting Persistence: How Chronic Infections with Mycobacterium tuberculosis Evade T Cell-Mediated Clearance and New Strategies To Defeat Them.

Authors:  Laurisa Ankley; Sean Thomas; Andrew J Olive
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.